B+
Bull case
25%
Probability
Target price
$3.50
Analysis reference price unavailable
Analysis 2026-06-11 · RankAlpha Sentiment Codex
ALLO
Allogene TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The strongest positive read-through is that Allogene now has more time to fund its key programs, while the stored Q1 earnings context points to directionally constructive ALPHA3 interim futility data and early ALLO-329 observations. If ALLO-329 continues to show tolerability and activity into the Q4 2026 update, investors could start to underwrite more than a one-asset story, but the evidence remains early [#SEC-8K-2026-05-13][#PR-EARNINGS-2026-05-14].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Clinical-risk concentration is high: the next meaningful upside case still depends on ALLO-329 and the longer-dated ALPHA3 EFS readout rather than current operating fundamentals [#SEC-8K-2026-05-13][#PR-EARNINGS-2026-05-14].
Momentum
96
Value
41
Sentiment
77
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.90 · Bull $3.50 · Bear $0.80Analysis 2026-06-11; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-11 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $8.75
Why
Momentum96 · Δ7d -
Value41 · Δ7d -0.0
Sentiment77 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Clinical-risk concentration is high: the next meaningful upside case still depends on ALLO-329 and the longer-dated ALPHA3 EFS readout rather than current operating fundamentals [#SEC-8K-2026-05-13][#PR-EARNINGS-2026-05-14].
- • Even with the reported runway extension into Q1 2029, Allogene remains precommercial, so any slippage in enrollment, dose optimization, or clinical readouts could quickly bring financing risk back into focus [#PR-EARNINGS-2026-05-14].
- • This is still a low-coverage, precommercial biotech with a stock that remains heavily dependent on future clinical proof.
Catalyst clock
2026-05-13
Q1 update and April financing eased the immediate balance-sheet overhang
Lead driver: Sentiment · See AI snapshot
Momentum
96
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
77
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 96.4 / Value 41.2 / Sentiment 76.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-11. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$1.90
Analysis reference price unavailable
Analysis 2026-06-11 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.80
Analysis reference price unavailable
Analysis 2026-06-11 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$718.62M
Beta
0.60
Shares Out
345.49M
P/E (TTM) · Derived
-2.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-5.09
Rev YoY
-100.0%
EPS YoY
-44.3%
Gross Margin
-151.5%
Op Margin
-1241814.0%
Net Debt
-$166.96M
Current Ratio
10.72
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data